SG11201810801QA - Brain delivery protein - Google Patents

Brain delivery protein

Info

Publication number
SG11201810801QA
SG11201810801QA SG11201810801QA SG11201810801QA SG11201810801QA SG 11201810801Q A SG11201810801Q A SG 11201810801QA SG 11201810801Q A SG11201810801Q A SG 11201810801QA SG 11201810801Q A SG11201810801Q A SG 11201810801QA SG 11201810801Q A SG11201810801Q A SG 11201810801QA
Authority
SG
Singapore
Prior art keywords
international
brain
stockholm
uppsala
brain delivery
Prior art date
Application number
SG11201810801QA
Inventor
Lars Lannfelt
Dag Sehlin
Greta Hultqvist
Stina Syvänen
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of SG11201810801QA publication Critical patent/SG11201810801QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70582—CD71

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111110111011111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/011353 Al 18 January 2018 (18.01.2018) W I P0 I PC T (51) International Patent Classification: (74) Agent: AWAPATENT AB; Box 45086, 104 30 Stockholm CO7K 16/18 (2006.01) A61K 39/00 (2006.01) (SE). C07K 16/28 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2017/067727 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 13 July 2017 (13.07.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, WV, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 1651065-3 14 July 2016 (14.07.2016) SE TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: BIOARCTIC AB [SE/SE]; Warfvinges vag 35, (84) Designated States (unless otherwise indicated, for every 112 51 Stockholm (SE). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: LANNFELT, Lars; c/o BioArctic AB, War- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, fvinges vag 35, 112 51 Stockholm (SE). SEHLIN, Dag; TM), European (AL, AT, BE, BG, DE, DK, — CH, CY, CZ, Basarbovagen 1, 752 73 Uppsala (SE). HULTQVIST, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Uppsala (SE). Greta; Hjalmar Brantingsgatan 2b, 753 27 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, SYVANEN, Stina; Akerholmsvagen 14, 755 98 Uppsala TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — (SE). KM, ML, MR, NE, SN, TD, TG). = = Title: BRAIN DELIVERY PROTEIN (54) = al = = = = = = = = = A B 1-1 .4 in en Figure 1 M Il (57) : The present invention relates to a brain delivery protein, comprising a target binding antibody which binds to a target 1-1 O in a mammalian brain; two carrier moieties, each of which being capable of monovalent interaction with a protein expressed on a -- -- GC blood brain barrier (BBB) endothelial cell, wherein each of said carrier moieties is linked to a C-terminal end of the target binding antibody. The present invention moreover relates to use of such brain delivery proteins in therapy or diagnosis or for research of e.g. 0 neurodegenerative disorders, and other brain diseases. ei C [Continued on next page] WO 2018/011353 Al DIII Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201810801QA 2016-07-14 2017-07-13 Brain delivery protein SG11201810801QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1651065 2016-07-14
PCT/EP2017/067727 WO2018011353A1 (en) 2016-07-14 2017-07-13 Brain delivery protein

Publications (1)

Publication Number Publication Date
SG11201810801QA true SG11201810801QA (en) 2019-01-30

Family

ID=59593007

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810801QA SG11201810801QA (en) 2016-07-14 2017-07-13 Brain delivery protein
SG10201912842VA SG10201912842VA (en) 2016-07-14 2017-07-13 Brain delivery protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912842VA SG10201912842VA (en) 2016-07-14 2017-07-13 Brain delivery protein

Country Status (15)

Country Link
US (1) US11498974B2 (en)
EP (1) EP3484918A1 (en)
JP (2) JP2019529345A (en)
KR (1) KR20190039696A (en)
CN (1) CN109476728A (en)
AU (1) AU2017297804A1 (en)
BR (1) BR112019000098A2 (en)
CA (1) CA3028035A1 (en)
IL (1) IL263773A (en)
MA (1) MA45684A (en)
MX (1) MX2019000529A (en)
PH (1) PH12018502451A1 (en)
RU (1) RU2019102746A (en)
SG (2) SG11201810801QA (en)
WO (1) WO2018011353A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2020097155A1 (en) * 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
BR112023025904A2 (en) 2021-06-11 2024-02-27 Bioarctic Ab BIESPECIFIC BINDING MOLECULE
WO2023215697A1 (en) * 2022-05-05 2023-11-09 Eli Lilly And Company Multispecific binding molecules and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (en) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Improved protofibril-selective antibodies and use thereof
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
CN102076339A (en) 2008-04-24 2011-05-25 百时美施贵宝公司 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2282758B1 (en) 2008-04-29 2018-11-21 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
RU2522245C2 (en) 2008-07-10 2014-07-10 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Methods and compositions for improved delivery of macromolecules
PT2448968T (en) 2009-06-29 2021-04-30 Bioarctic Ab N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer`s disease
PT2539366T (en) 2010-02-26 2018-02-13 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
RU2635999C2 (en) * 2010-06-17 2017-11-17 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Antibodies suitable for passive immunization against influenza
SI2646470T1 (en) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
CN104520329A (en) 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 Blood brain barrier shuttle
RU2699289C2 (en) * 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. Nucleic acids encoding human antibodies to sialyl-lewisa
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
KR20230129449A (en) * 2014-07-10 2023-09-08 바이오악틱 에이비 Improved Aβ Protofibril Binding Antibodies

Also Published As

Publication number Publication date
RU2019102746A (en) 2020-08-14
MX2019000529A (en) 2020-01-15
JP2022130646A (en) 2022-09-06
EP3484918A1 (en) 2019-05-22
PH12018502451A1 (en) 2019-09-30
RU2019102746A3 (en) 2020-11-30
JP2019529345A (en) 2019-10-17
US20190225699A1 (en) 2019-07-25
SG10201912842VA (en) 2020-02-27
AU2017297804A1 (en) 2019-01-24
CA3028035A1 (en) 2018-01-18
IL263773A (en) 2019-02-28
MA45684A (en) 2019-05-22
CN109476728A (en) 2019-03-15
BR112019000098A2 (en) 2019-04-09
WO2018011353A1 (en) 2018-01-18
US11498974B2 (en) 2022-11-15
KR20190039696A (en) 2019-04-15

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201810801QA (en) Brain delivery protein
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof